BridgeBio Files for 24.6M Share Offering by Selling Stockholders
BBIO sits 100% above its 52-week low of $42.09.
Summary
BridgeBio Pharma filed for an offering of up to 24.6 million common shares by selling stockholders. At the current $84 price, that's roughly $2.1 billion in potential selling pressure, though the actual amount and timing depend on the sellers. This follows a $1 billion convertible preferred equity raise earlier this month and a $500 million at-the-market program authorized in May. The filing adds to a pattern of significant capital market activity, and traders will watch for the prospectus supplement detailing the actual terms and selling stockholders.
At the time of this announcement, BBIO was trading at $84.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5B. The 52-week trading range was $42.09 to $93.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.